Emmaus Life Sciences Q1 revenue falls driven by lower sales in U.S.

Emmaus Life Sciences

15/05/2026 21:00

Overview

U.S. biopharma's Q1 revenue fell 18% yr/yr as U.S. sales declined amid generic competition

Operating loss narrowed 16% yr/yr due to cost reduction initiatives

Net loss widened, mainly due to higher interest and derivative expenses

Outlook

Company did not provide specific guidance or outlook for future periods

Result Drivers

GENERIC COMPETITION - Co said 33% decrease in U.S. sales was due to competition from generic L-Glutamine

MENA SALES GROWTH - 94% increase in MENA region sales partially offset U.S. decline

COST REDUCTION - Lower operating expenses due to reduced headcount and other cost cutting measures

Company press release: ID:nBwxrtbCa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
$1.98 mln
Q1 EPS
-$0.05
Q1 Net Income
-$3.34 mln
Q1 Gross Profit
$1.81 mln
Q1 Income from Operations
-$823,000
Q1 Operating Expenses
$2.64 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)